FIELD: pharmaceutics and medicine; neurology.
SUBSTANCE: invention is intended for the treatment of patients with Alzheimer's disease and for the prevention of its development. The following is disclosed: the use of a benzopyran derivative, namely 3-(3-,4-dihydro-6,7-dimethoxy-3,3-dimethyl-1-isoquinolinyl)-2H-1-benzopyran-2-one of formula (I), as a medicinal product intended for the prevention and/or treatment of a neurodegenerative disease, which is Alzheimer's disease and/or dementia of the Alzheimer's type.
(I)
EFFECT: use of the invention makes it possible to effectively treat Alzheimer's disease and/or dementia of the Alzheimer's type.
1 cl, 9 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF THE PIPERAZIN DERIVATIVES FOR TREATMENT OF THE ALZHEIMER'S DISEASE AND THE ALZHEIMER'S TYPE DEMENTIA WITH DISTURBED VENTRICULAR CALCIUM SIGNALING | 2018 |
|
RU2676100C1 |
| REDUCED SYSTEMIC LEVEL OF REGULATORY T-CELLS OR THEIR ACTIVITY FOR TREATING CNS DISEASES AND TRAUMAS | 2016 |
|
RU2741366C2 |
| HYDROCORTISONE DERIVATIVE FOR ALZHEIMER'S DISEASE TREATMENT | 2019 |
|
RU2748437C2 |
| 4-(3-((2-ADAMANTYL)AMINO)-3-OXOPROP-1-EN-1-YL)-N-HYDROXYBENZAMIDE - A NEW DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 2022 |
|
RU2783995C1 |
| METHYLTHIONINIUM AS COGNITIVE ENHANCER | 2020 |
|
RU2824584C2 |
| TREATMENT OF NEUROLOGICAL DISEASES | 2017 |
|
RU2755997C2 |
| REDUCED SYSTEMIC LEVELS OR ACTIVITY OF REGULATORY T-CELLS FOR TREATING DISEASE AND CENTRAL NERVOUS SYSTEM INVOLVEMENT | 2017 |
|
RU2815892C1 |
| METHOD FOR TREATING NEURODEGENERATIVE DISEASES | 2021 |
|
RU2777871C1 |
| TARGETED NON-INVASIVE TRANSPLANTATION INTO BRAIN OF FUNCTIONALLY ACTIVE MITOCHONDRIA FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2744453C2 |
| HERBAL EXTRACTS FOR TREATING NEURODEGENERATIVE DISEASES | 2010 |
|
RU2559088C2 |
